Investor Presentaiton

US MARKET FOCUS- COMPLEX GENERICS & FRONTEND KEY PRODUCTS IN THE PORTFOLIO (1) Afinitor(2.5 mg, 5 mg, 7.5 Tykerb Zortress Molecule Lenalidomide Glatiramer Acetate Oseltamivir Everolimus (higher strength) Lanthanum Carbonate Liposomal Doxorubicin LapatinibDitosylate Everolimus (lower strength) NATCO Therapeutic Segment / Primary Indication Cancer/Multiple Myeloma CNS/Multiple Sclerosis Anti-Viral/Influenza Cancer/Breast Renal disease Cancer/Ovarian and other Cancer/Breast Immunosupressant/Organ Transplant Predominantly focused on high-barrier-to-entry products that are typically characterized by one or more of the following: Intricate Chemistry ■ Challenging delivery systems Difficult or complex manufacturing process Will continue to work with partners for complex products or those involving unique patent challenges Low risk business model; through partnerships with global pharmaceutical players ■ Marketing partner typically responsible for litigation and regulatory process to secure ANDA approval. Multi-site approvals ■ Multi-sourcing arrangements Launched Ondansetron, Nitroglycerin and Armodafinil through NATCO Pharma USA LLC. Revlimid Key Brand Copaxone Tamiflu mg and 10 mg) Fosrenol Doxil PIPELINE OF NICHE IN THE US 23 Para IVs in the pipeline (2) Of which 15 are approved (2) (either tentative or fully). SOLO FIRST TO FILE IN THE PIPELINE (1) Key Brand Key Brand Molecule Therapeutic Segment / Primary Indication Eliquis Apixaban KEY PARA IV PRODUCTS IN THE PIPELINE (1) Molecule Therapeutic Segment / Primary Indication Anticogulant Ozempic Semaglutide pen Diabetes Tracleer Kyprolis Imbruvica Ibrutinib (tablet) Bosentan (32mg) Anti-hypertensive Lynparza Olaparib Carfilzomib (10mg) Cancer/Multiple Myeloma Kyprolis Carfilzomib Cancer/Leukaemia Imbruvica Zydelig Lynparza Ozempic Balversa Idelalisib Cancer Pomalyst Olaparib Semaglutide pen (8mg/3ml) Erdafitinib Ovarian/Breast Cancer Lonsurf Ibrutinib Pomalidomide Trifluridine/Tipracil Ovarian/Breast Cancer Cancer/Multiple Myeloma Cancer/Leukaemia Cancer/Multiple Myeloma Metastatic colorectal cancer Diabetes Bladder Cancer 1.As of Sept 30, 2023 2. As of Sept 30, 2023. Approval received either by Natco or its marketing partner Yondelis Trabectedin Calquence Zydelig Acalabrutinib Idelalisib Advanced soft-tissue sarcoma/ ovarian cancer Cancer/Blood Cancer 6

View entire presentation